Drug Trial Radar · NCT01484496
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
839
Actual
Start
Nov 16, 2011
Primary completion
Feb 13, 2015
Study completion Oct 1, 2015
Sponsor
- Lead sponsor
- Human Genome Sciences Inc., a GSK CompanyIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Dec 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus
Interventions
PlaceboBiological
Placebo
Belimumab 200 mg SCBiological
Belimumab 200 mg SC
Standard therapyDrug
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52Time frame: Week 52
Locations
207 sites in 31 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Peoria, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Jonesboro, Arkansas
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
San Leandro, California
GSK Investigational Site
Tustin, California
GSK Investigational Site
Upland, California
GSK Investigational Site
Bridgeport, Connecticut
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Boca Raton, Florida
GSK Investigational Site
Coral Gables, Florida
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Plantation, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Duluth, Georgia
GSK Investigational Site
Lawrenceville, Georgia
GSK Investigational Site
Marietta, Georgia
GSK Investigational Site
Boise, Idaho
GSK Investigational Site
Springfield, Illinois
GSK Investigational Site
Baton Rouge, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Baltimore, Maryland
GSK Investigational Site
Cumberland, Maryland
GSK Investigational Site
Hagerstown, Maryland
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Detroit, Michigan
Showing 40 of 207 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.